Related Experiment Videos
Antibody-dependent cell-mediated cytotoxicity against mouse MM2 tumor cell line by macrophages activated with OK-432
Abstract:
The action mechanism of antibody-dependent macrophage-mediated cytotoxicity (ADMC) induced by OK-432 against MM2 carcinoma cells was examined. Adherent peritoneal exudate cells (adherent PEC) harvested from mice 4 days after intraperitoneal injection of OK-432 exhibited potent cytotoxic activity against MM2 cells in the presence of anti-serum obtained from tumor-free mice which had survived over 60 days following treatment with OK-432 and resisted rechallenge with MM2 cells. The cytotoxic activity of the adherent PEC was not abolished by treatment with anti-Thy-1.2 and complement, and there were no differences in ADMC between adherent PEC from BALB/c mice and those from athymic BALB/c (nu/nu) mice. Further, ADMC activity was shown not only against MM2 cells, but also against other allogeneic tumor cells, such as MOPC-11 plasmacytoma cells. On the other hand, the effective factor(s) in anti-serum to MM2 cells was eliminated by passage through a protein A-Sepharose CL-4B affinity column. The action mechanism of ADMC caused by the adherent PEC and anti-serum to MM2 cells is discussed.
Insights
OK-432 immunotherapy activates antibody-dependent macrophage-mediated cytotoxicity (ADMC) against carcinoma cells. This immune response involves specific antibodies and macrophages, offering a potential mechanism for cancer treatment.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- OK-432 is an immunotherapy agent used to stimulate immune responses.
- Antibody-dependent macrophage-mediated cytotoxicity (ADMC) is a key immune mechanism for tumor cell killing.
- Understanding the precise mechanisms of ADMC is crucial for developing effective cancer therapies.
Purpose of the Study:
- To elucidate the action mechanism of antibody-dependent macrophage-mediated cytotoxicity (ADMC) induced by OK-432 against MM2 carcinoma cells.
- To identify the cellular components and serum factors involved in OK-432-mediated ADMC.
Main Methods:
- Harvesting adherent peritoneal exudate cells (adherent PEC) from mice treated with OK-432.
- Assessing cytotoxic activity of adherent PEC against MM2 cells in the presence of specific anti-serum.
- Utilizing anti-Thy-1.2 and complement treatment to characterize cell populations.
- Comparing ADMC activity in immunocompetent and athymic mice.
- Testing ADMC activity against various allogeneic tumor cells.
- Employing protein A-Sepharose CL-4B affinity chromatography to isolate active serum factors.
Main Results:
- Adherent PEC from OK-432-treated mice demonstrated potent cytotoxic activity against MM2 cells when combined with specific anti-serum.
- The cytotoxic activity was independent of T-cells (not abolished by anti-Thy-1.2 and complement) and observed in both immunocompetent and athymic mice.
- ADMC activity was effective against multiple tumor cell types, including MOPC-11 plasmacytoma.
- The effective factor in the anti-serum was identified as a protein, confirmed by affinity chromatography.
Conclusions:
- OK-432 immunotherapy effectively induces ADMC against carcinoma cells via specific antibodies and macrophages.
- The mechanism involves non-T-cell dependent macrophage activation and is effective against a range of tumor types.
- Further research into these antibody and macrophage interactions could lead to novel cancer treatment strategies.